Literature DB >> 2171221

Different effects of IFN gamma and IFN alpha/beta on "immediate early" gene expression of HSV-1.

A Klotzbücher1, S Mittnacht, H Kirchner, H Jacobsen.   

Abstract

The effects of interferon gamma (IFN gamma) on early steps of herpes simplex virus (Type 1; HSV-1) replication in primary cultures of splenic mouse macrophages were analyzed and compared to IFN alpha/beta. Pretreatment of macrophages with recombinant murine IFN gamma led to a dose-dependent reduction in the yield of progeny virus. Inhibition of protein synthesis was observed for HSV-1 alpha, beta and gamma-proteins. Expression of the "immediate early" (IE) gene IE3 (ICP4) was investigated in detail. Steady-state level of the RNA and transcriptional activity of the gene in IFN gamma-treated cells were comparable to control-infected cells except for a delay in their kinetics. This is in contrast to IFN alpha/beta, which leads to a stable decrease in IE3 transcripts. Since IFN gamma causes a stable decrease in the IE3 gene product ICP4, our data suggest a translational inhibition of HSV-1 IE gene expression in IFN gamma-treated macrophages. Thus, IFN gamma and IFN alpha/beta inhibit HSV-1 replication by different mechanisms which may lead to a synergistic enhancement of inhibition after combined treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171221     DOI: 10.1016/0042-6822(90)90322-i

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection.

Authors:  Kasey M Eidson; William E Hobbs; Brian J Manning; Paul Carlson; Neal A DeLuca
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression.

Authors:  Dmitri G Negorev; Olga V Vladimirova; Alexey Ivanov; Frank Rauscher; Gerd G Maul
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission.

Authors:  Z Mikloska; A L Cunningham
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 4.  Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Authors:  Balveen Kaur; E Antonio Chiocca; Timothy P Cripe
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

5.  Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2.

Authors:  G N Milligan
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Inhibition by interferon of herpes simplex virus type 1-activated transcription of tat-defective provirus.

Authors:  W Popik; P M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

7.  Herpes simplex virus type 2-mediated disease is reduced in mice lacking RNase L.

Authors:  Rebecca J Duerst; Lynda A Morrison
Journal:  Virology       Date:  2006-12-06       Impact factor: 3.616

8.  Ectopic expression of gamma interferon in the eye protects transgenic mice from intraocular herpes simplex virus type 1 infections.

Authors:  K Geiger; E L Howes; N Sarvetnick
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Dysregulated expression of IFN-gamma and IL-10 and impaired IFN-gamma-mediated responses at different disease stages in patients with genital herpes simplex virus-2 infection.

Authors:  R Singh; A Kumar; W D Creery; M Ruben; A Giulivi; F Diaz-Mitoma
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

10.  Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response.

Authors:  Donald Y M Leung; Pei-Song Gao; Dmitry N Grigoryev; Nicholas M Rafaels; Joanne E Streib; Michael D Howell; Patricia A Taylor; Mark Boguniewicz; Jennifer Canniff; Brian Armstrong; Daniel J Zaccaro; Lynda C Schneider; Tissa R Hata; Jon M Hanifin; Lisa A Beck; Adriana Weinberg; Kathleen C Barnes
Journal:  J Allergy Clin Immunol       Date:  2011-04       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.